Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADG126 plus pembrolizumab in advanced/metastatic solid tumors
CTR20241474Phase 2Active
- Sponsor
- Adagene
- Start
- Sep 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of muzastotug, pembrolizumab in colorectal cancer (CRC), non-small cell lung cancer (NSCLC), sponsored by Adagene. Started Sep 2024; status: active.
02
Drugs
muzastotugpembrolizumab
03
Conditions
colorectal cancer (CRC)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20241474.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20241474.